The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...
Two public companies focused on RNA editing therapies, Korro Bio and ProQR, enjoyed impressive stock surges powered by their best-ever one day gains; their share prices lifted by Wave Life Sciences ...